First-Hand Look at India's Pharma Services Sector - Indian manufacturers are not now a threat to Western CMOs, but may be long term. - BioPharm International


First-Hand Look at India's Pharma Services Sector
Indian manufacturers are not now a threat to Western CMOs, but may be long term.

BioPharm International
Volume 24, Issue 3, pp. 18-19


We also visited dedicated contract services companies offering discovery, API process development, and formulation-development services, along with clinical-scale manufacturing. These companies are largely targeting Western bio/pharmaceutical companies as their key clients, although they are finding clients within India as well. The impression left by these companies was decidedly mixed. Some reflected a high level of sophistication and understanding of what Western companies are looking for and expect, and others offered barebones facilities that generally would not pass muster with prospective clients from major bio/pharmaceutical companies.

The performance of these services-only companies varied. Those offering discovery and process-development services appear to be doing quite well while those offering formulation-development and early-stage clinical trial material (CTM) services are not as robust. The global bio/pharmaceutical companies began turning to Indian and Chinese CROs for discovery and process chemistry services almost 10 years ago, and several companies have emerged as world-class service providers. We visited the Hyderabad campuses of two of industry leaders in chemistry outsourcing, GVK Bio and Aptuit, and came away impressed with the sophistication of their leadership and quality of their facilities and operations.

The challenge for formulation-development companies seems to be two-fold: the local market for CTM is somewhat limited because bio/pharmaceutical companies cannot conduct first-in-man studies in India, and expenditures for early formulation-development services are so low at most Western companies these days that the expected cost savings from going to India are minimal. Near term, we think those companies are going to have to establish a laboratory presence in Western markets to capture that early-phase business, with the intention that the products can be transitioned to Indian facilities as the products approach commercialization. Longer term, the formulation-development CROs will benefit as global bio/pharmaceutical companies establish more R&D operations in India and source more of their needs locally.

My overall conclusion is India is building a base for a strong local contract services industry in the coming years. The threat for Western contract development and manufacturing organizations (CDMOs) and CMOs is small in the near-term, but as global bio/pharmaceutical companies target this fast-growing market, Indian firms will be well-positioned to seize the opportunity.

Jim Miller is president of PharmSource Information Services, Inc., Springfield, VA, 703.383.4903,

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here